Locked and loaded: strong TCR signaling primes anti-PD-1 therapy

Abstract

With continuous T cell receptor (TCR) signaling, T cells can attenuate subsequent antigen responses through adaptive tolerance, thus averting autoimmunity, but potentially also providing refuge to developing cancers. Elliot and coworkers add to our understanding of adaptation via immune checkpoints by exploiting accelerated in vivo adaptive tolerance in the face of strong TCR signaling.